Literature DB >> 9695145

Morphine has a dual concentration-dependent effect on K(+)-evoked substance P release from rat peripheral airways.

P J Cabot1, T Cramond, M T Smith.   

Abstract

Our previous investigations of possible lung mechanisms underlying the effectiveness of nebulized morphine for the relief of dyspnoea, have shown a high density of non-conventional opioid binding sites in rat airways with similar binding characteristics (opioid alkaloid-sensitive, opioid peptide-insensitive) to that of putative mu 3-opioid receptors on immune cells. To investigate whether these lung opioid binding sites are functional receptors, this study was designed to determine (using superfusion) whether morphine modulates the K(+)-evoked release of the pro-inflammatory neuropeptide, substance P (SP), from rat peripheral airways. Importantly, K(+)-evoked SP release was Ca(2+)-dependent, consistent with vesicular release. Submicromolar concentrations of morphine (1 and 200 nM) inhibited K(+)-evoked SP release from rat peripheral airways in a naloxone (1 microM) reversible manner. By contrast, 1 microM morphine enhanced K(+)-evoked SP release and this effect was not reversed by 1 microM naloxone. However, 100 microM naloxone not only antagonized the facilitatory effect of 1 microM morphine on K(+)-evoked SP release from rat peripheral airways but it inhibited release to a similar extent as 200 nM morphine. It is possible that these latter effects are mediated by non-conventional opioid receptors located on mast cells, activation of which causes naloxone-reversible histamine release that in turn augments the release of SP from sensory nerve terminals in the peripheral airways. Clearly, further studies are required to investigate this possibility.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9695145     DOI: 10.1006/pupt.1997.0094

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  3 in total

1.  The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide.

Authors:  Richard T Penson; Simon P Joel; Michael Roberts; Anna Gloyne; Stephen Beckwith; Maurice L Slevin
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

Review 2.  Neuronal mechanisms underlying opioid-induced respiratory depression: our current understanding.

Authors:  Jan-Marino Ramirez; Nicholas J Burgraff; Aguan D Wei; Nathan A Baertsch; Adrienn G Varga; Helen A Baghdoyan; Ralph Lydic; Kendall F Morris; Donald C Bolser; Erica S Levitt
Journal:  J Neurophysiol       Date:  2021-04-07       Impact factor: 2.714

3.  Effect of nebulized morphine on dyspnea of mustard gas-exposed patients: a double-blind randomized clinical trial study.

Authors:  Majid Shohrati; Mostafa Ghanei; Asghar Amini Harandi; Soniya Foroghi; Ali Amini Harandi
Journal:  Pulm Med       Date:  2012-03-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.